Compare Constellation Energy Corporation (CEG) vs Novo Nordisk A/S (NVO) Price & Performance

Constellation Energy CorporationTrade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Constellation Energy Corporation vs Novo Nordisk A/S — how do they compare? Constellation Energy Corporation trades at $279.66 (market cap $98.63B), while Novo Nordisk A/S trades at $46.23 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.1× Constellation Energy Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.

	CEG	NVO
Market Cap	$98.63B	$207.85B
Sector	Energy	Health
52-Week High	$403.95	$63.98
52-Week Low	$236.50	$35.29
Enterprise Value	$122.63B	$222.55B
Dividend Yield	0.61%	3.81%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Constellation Energy Corporation

Constellation Energy (CEG) is trading at $281.84, up 4.22% today, with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS of $2.55 beating expectations by 11.4%, and raised 2026 guidance. Recent news highlights nuclear power contracts with major tech companies driving growth. Technical indicators show bullish momentum with support at $277 and resistance at $282.

CEG presents a compelling investment case with strong earnings momentum, AI-driven power demand tailwinds, and 70% analyst buy ratings. Risks include execution of nuclear capacity expansion and potential regulatory changes. The consensus price target of $332.13 suggests 18% upside potential from current levels.

Novo Nordisk A/S

NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.

The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

CEG

Constellation Energy rated Strong Buy with price target raised to $449 on AI-driven nuclear contract growth.Seeking Alpha · 1 day agoBullish View details →

NVO

Novo Nordisk stays a Buy with strong obesity drug lead and improved 2026 outlook despite near-term challenges.Seeking Alpha · 5 hours agoBullish Novo Nordisk faces sell rating amid rising competition and operational challenges, with price target cut to $47.Alex Lavoie · 6 hours agoBearish View details →

About Constellation Energy Corporation

Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.